D. E. Shaw & Co., Inc. Puma Biotechnology, Inc. Transaction History

D. E. Shaw & Co., Inc.

$156 Billion
Q3 2025

A detailed history of D. E. Shaw & Co., Inc. transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 498,598 shares of PBYI stock, worth $2.47 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

498,598

Previous 640,780 22.19%

Holding current value

$2.47 Million

Previous $2.2 Million 16.39%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$3.07 - $5.73 $436,498 - $814,702	-142,182 Reduced 22.19%	498,598 $2.56 Million
Q2 2025 Aug 14, 2025	BUY	$2.74 - $3.72 $189,375 - $257,107	69,115 Added 12.09%	640,780 $2.2 Million
Q1 2025 May 15, 2025	BUY	$2.76 - $3.88 $963,397 - $1.35 Million	349,057 Added 156.8%	571,665 $1.69 Million
Q4 2024 Feb 14, 2025	BUY	$2.42 - $3.39 $399,832 - $560,095	165,220 Added 287.9%	222,608 $678,000
Q3 2024 Nov 14, 2024	BUY	$2.25 - $4.03 $129,123 - $231,273	57,388 New	57,388 $146,000

Q4 2022 Feb 14, 2023	SELL	$2.12 - $5.08 $861,483 - $2.06 Million	-406,360 Reduced 75.46%	132,184 $559,000
Q3 2022 Nov 14, 2022	SELL	$2.27 - $3.84 $956,868 - $1.62 Million	-421,528 Reduced 43.91%	538,544 $1.28 Million
Q2 2022 Aug 15, 2022	SELL	$1.64 - $3.3 $75,294 - $151,506	-45,911 Reduced 4.56%	960,072 $2.74 Million
Q1 2022 May 16, 2022	BUY	$2.13 - $3.24 $575,144 - $874,868	270,021 Added 36.69%	1,005,983 $2.9 Million
Q4 2021 Feb 14, 2022	BUY	$2.85 - $6.58 $1.95 Million - $4.51 Million	685,690 Added 1363.96%	735,962 $2.24 Million
Q3 2021 Nov 15, 2021	SELL	$6.63 - $9.39 $405,981 - $574,987	-61,234 Reduced 54.92%	50,272 $352,000
Q2 2021 Aug 16, 2021	BUY	$8.98 - $11.6 $281,163 - $363,196	31,310 Added 39.04%	111,506 $1.02 Million
Q1 2021 May 17, 2021	BUY	$9.38 - $13.63 $425,730 - $618,624	45,387 Added 130.39%	80,196 $780,000
Q4 2020 Feb 16, 2021	BUY	$7.78 - $12.13 $35,725 - $55,700	4,592 Added 15.2%	34,809 $357,000
Q3 2020 Nov 16, 2020	SELL	$9.5 - $11.14 $1.52 Million - $1.78 Million	-159,794 Reduced 84.1%	30,217 $305,000
Q2 2020 Aug 14, 2020	BUY	$7.01 - $13.24 $237,765 - $449,074	33,918 Added 21.73%	190,011 $1.98 Million
Q1 2020 May 15, 2020	SELL	$6.28 - $14.57 $952,839 - $2.21 Million	-151,726 Reduced 49.29%	156,093 $1.32 Million
Q4 2019 Feb 14, 2020	BUY	$6.5 - $10.73 $464,431 - $766,669	71,451 Added 30.23%	307,819 $2.69 Million
Q3 2019 Nov 14, 2019	SELL	$8.75 - $12.85 $1.53 Million - $2.24 Million	-174,432 Reduced 42.46%	236,368 $2.55 Million
Q2 2019 Aug 14, 2019	SELL	$12.3 - $35.76 $1.04 Million - $3.02 Million	-84,426 Reduced 17.05%	410,800 $5.22 Million
Q1 2019 May 15, 2019	BUY	$20.77 - $42.37 $8.85 Million - $18 Million	425,991 Added 615.28%	495,226 $19.2 Million
Q4 2018 Feb 14, 2019	SELL	$20.07 - $46.7 $3.81 Million - $8.87 Million	-189,867 Reduced 73.28%	69,235 $1.41 Million
Q3 2018 Nov 14, 2018	SELL	$41.2 - $59.85 $22 Million - $31.9 Million	-533,442 Reduced 67.31%	259,102 $11.9 Million
Q2 2018 Aug 14, 2018	SELL	$48.3 - $68.25 $28.1 Million - $39.8 Million	-582,501 Reduced 42.36%	792,544 $46.9 Million
Q1 2018 May 15, 2018	BUY	$59.7 - $99.25 $25.6 Million - $42.5 Million	428,467 Added 45.26%	1,375,045 $93.6 Million
Q4 2017 Feb 14, 2018	BUY	$93.85 - $132.45 $80.5 Million - $114 Million	857,667 Added 964.64%	946,578 $93.6 Million
Q3 2017 Nov 14, 2017	BUY	$72.0 - $119.75 $6.4 Million - $10.6 Million	88,911	88,911 $10.6 Million

Others Institutions Holding PBYI

# of Institutions

135

Shares Held

35.2M

Call Options Held

264K

Put Options Held

View Full List

About PUMA BIOTECHNOLOGY, INC.

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $226M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

More about PBYI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account